Furthermore, we found that serum anti-LAMP-2 antibody levels were remarkably increased in VAS-HTN patients with active stages compared with those in inactive stage patients ((139.65 ± 54.02) vs. (102.47 ± 49.48) ng/ml, P=0.004) (Figure 3(b)). This evidence concerns the gene LAMP2 and hypertensive disorder.